Optimal diuretic strategies in heart failure

被引:8
|
作者
Suri, Sarabjeet S. [1 ]
Pamboukian, Salpy V. [1 ]
机构
[1] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA
关键词
Heart failure (HF); diuresis; diuretic resistance; FUROSEMIDE; TOLVAPTAN;
D O I
10.21037/atm-20-4600
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Heart failure (HF) is one of the major causes of morbidity and mortality in the world. According to a 2019 American Heart Association report, about 6.2 million American adults had HF between 2013 and 2016, being responsible for almost 1 million admissions. As the population ages, the prevalence of HF is anticipated to increase, with 8 million Americans projected to have HF by 2030, posing a significant public health and financial burden. Acute decompensated HF (ADHF) is a syndrome characterized by volume overload and inadequate cardiac output associated with symptoms including some combination of exertional shortness of breath, orthopnea, paroxysmal nocturnal dyspnea (PND), fatigue, tissue congestion (e.g., peripheral edema) and decreased mentation. The pathology is characterized by hemodynamic abnormalities that result in autonomic imbalance with an increase in sympathetic activity, withdrawal of vagal activity and neurohormonal activation (NA) resulting in increased plasma volume in the setting of decreased sodium excretion, increased water retention and in turn an elevation of filling pressures. These neurohormonal changes are adaptive mechanisms which in the short term are associated with increased contractility of the left ventricular (LV) and improvement in cardiac output. But chronically, the failing heart is unable to overcome the excessive pressure and volume leading to worsening HF. The primary symptomatic management of ADHF includes intravenous (IV) diuresis to help with decongestion and return to euvolemic status. Even though diuretics have not been shown to provide any mortality benefit, they have been clinically proven to be of significant benefit in the acute decompensated phase, as well as in chronic management of HF. Loop diuretics remain the mainstay of therapy for symptomatic management of HF with use of thiazide diuretics for synergistic effect in the setting of diuretic resistance. Poor diuretic efficacy has been linked with higher mortality and increased rehospitalizations.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Prognostic Implications of Diuretic Dose in Chronic Heart Failure
    Martins, Joao
    Lourenco, Patricia
    Araujo, Jose Paulo
    Mascarenhas, Joana
    Lopes, Ricardo
    Azevedo, Ana
    Bettencourt, Paulo
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2011, 16 (02) : 185 - 191
  • [42] Impact of Loop Diuretic on Outcomes in Patients with Heart Failure and Reduced Ejection Fraction
    Antonietta, Cicoira Maria
    Calvi, Emiliano
    Faggiano, Andrea
    Maffeis, Caterina
    Bosisio, Marco
    De Stefano, Marco
    Carugo, Stefano
    Faggiano, Pompilio
    CURRENT HEART FAILURE REPORTS, 2022, 19 (01) : 15 - 25
  • [43] Evaluation of diuretic efficiency of intravenous furosemide in patients with advanced heart failure in a heart failure clinic
    Herrera-Leano, Nancy
    Barahona-Correa, Julian E.
    Munoz-Velandia, Oscar
    Fernandez-Avila, Daniel G.
    Marino-Correa, Alejandro
    Garcia, Angel-Alberto
    THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE, 2023, 17
  • [44] Contemporary Decongestive Strategies in Acute Heart Failure
    Kazory, Amir
    SEMINARS IN NEPHROLOGY, 2024, 44 (02)
  • [45] Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure
    ter Maaten, Jozine M.
    Rao, Veena S.
    Hanberg, Jennifer S.
    Wilson, F. Perry
    Bellumkonda, Lavanya
    Assefa, Mahlet
    Broughton, J. Sam
    D'Ambrosi, Julie
    Tang, W. H. Wilson
    Damman, Kevin
    Voors, Adriaan A.
    Ellison, David H.
    Testani, Jeffrey M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (08) : 1014 - 1022
  • [46] Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials
    Kiernan, Michael S.
    Stevens, Susanna R.
    Tang, W. H. Wilson
    Butler, Javed
    Anstrom, Kevin J.
    Birati, Edo Y.
    Grodin, Justin L.
    Gupta, Divya
    Margulies, Kenneth B.
    Larue, Shane
    Davila-Roman, Victor G.
    Hernandez, Adrian F.
    De Las Fuentes, Lisa
    JOURNAL OF CARDIAC FAILURE, 2018, 24 (07) : 428 - 438
  • [47] Potent potentiating diuretic effects of prednisone in congestive heart failure
    Liu, Chao
    Chen, Hua
    Zhou, Caixia
    Ji, Zhenguo
    Liu, Gang
    Gao, Yanqiu
    Tian, Li
    Yao, Li
    Zheng, Ye
    Zhao, Qingzhen
    Liu, Kunshen
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2006, 48 (04) : 173 - 176
  • [48] Diuretic therapy choice in the treatment of arterial hypertension and heart failure
    Savenkov, M. P.
    Kirichenko, A. V.
    Ivanov, S. N.
    Borshchevskaya, M. V.
    Okuneva, I. N.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2009, 8 (01): : 56 - 61
  • [49] Activity With Ambulation Attenuates Diuretic Responsiveness in Chronic Heart Failure
    Galiwango, Paul J.
    McReynolds, Andrew
    Ivanov, Joan
    Chan, Chris T.
    Floras, John S.
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (10) : 797 - 803
  • [50] Should torsemide be the loop diuretic of choice in systolic heart failure?
    DiNicolantonio, James J.
    FUTURE CARDIOLOGY, 2012, 8 (05) : 707 - 728